Moderna, Inc. (MUN:0QF)
Germany
· Delayed Price · Currency is EUR | Market Cap | 17.91B |
| Revenue (ttm) | 1.66B |
| Net Income (ttm) | -2.40B |
| Shares Out | n/a |
| EPS (ttm) | -6.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50 |
| Average Volume | 210 |
| Open | 43.39 |
| Previous Close | n/a |
| Day's Range | 43.39 - 43.75 |
| 52-Week Range | 20.18 - 44.09 |
| Beta | n/a |
| RSI | 70.52 |
| Earnings Date | Feb 13, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Moderna's Covid-Flu Vaccine Recommended for Approval in EU
The recommendation from regulators paves the way for the shot's approval in the European Union at a time the company is facing scrutiny in the U.S.
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive a positive CHMP opinion recommending marketing authorization and represents Moderna's fourth vaccine to receive a positive ...
Moderna gets EU regulator nod for combined COVID, flu vaccine
Europe's medicines regulator on Friday recommended granting marketing authorisation to mCombriax, making Moderna's messenger RNA vaccine the world's first combined shot for people aged 50 and older ag...
Moderna Stock: How Far Can The Flu Shot Fly?
Moderna (MRNA) – a developer of mRNA-focused therapeutics and vaccines – has recorded a 6-day winning streak, accumulating gains of 25% during this time. The company's market capitalization has increa...
US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost
U.S. Food and Drug Administration Commissioner Marty Makary on Monday defended his agency's position and record on mRNA vaccines, days after it changed course and agreed to review a Moderna flu vaccin...
BioNTech sues Moderna for patent infringement over COVID-19 shots
Biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging that Moderna's COVID-19 vaccine mNexspike infringes a patent related to BioNTech and Pfizer's competing ...
Moderna to Present at Upcoming Conferences in March 2026
CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / February 19, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 46th Annual Hea...
FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars
The stock's movement comes after the U.S. Food and Drug Administration (FDA) notified Moderna that its biologics license application for mRNA-1010 will proceed to review, adding pressure as broader ma...
FDA agrees to review Moderna's mRNA flu vaccine application in a reversal
Moderna said the Food and Drug Administration has agreed to review its experimental mRNA flu shot, reversing an earlier decision to refuse to accept the application. The FDA is slated to make a decisi...
Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccine
The FDA's “refuse-to-file” letter sent to reject Moderna's application is a rarity: A 2021 study found that 4% of the nearly 2,500 applications submitted to the agency receive such letters, many of wh...
Moderna got the FDA to change its mind and review its flu vaccine after some concessions
Moderna's stock was surging after the FDA said it would review the biotech's flu-vaccine candidate, a week after it had refused to do so.
FDA reverses decision not to review Moderna's new flu vaccine
The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday.
Moderna Says FDA Will Review Its Flu Vaccine. The Stock Is Rising.
The U.S. Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month.
The FDA reversed course and agreed to begin a review of Moderna's seasonal flu shot
The company's mRNA flu shot, if approved, could be available for the 2026-27 flu season.
Health Rounds: Moderna combo flu/COVID vaccine succeeds in mid-stage trial
A two-in-one mRNA vaccine developed by Moderna that targets seasonal influenza and COVID-19 produced robust and durable immune responses without safety concerns in a small mid-stage trial, the company...
US FDA to initiate review of Moderna's influenza vaccine
Moderna said on Wednesday the U.S. Food and Drug Administration has accepted its application to review its influenza vaccine candidate.
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
Following a Type A meeting, the FDA's Center for Biologics Evaluation and Research has notified Moderna that its biologics license application for mRNA-1010 will proceed to review Moderna has received...
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
mNEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe CAMBRIDGE, MA / ACCESS Newswire / February 17, 2026 / Moder...
Moderna, Inc. (MRNA) Price Forecast: Breakout Signals New Bull Trend
MRNA is showing early signs of a new bull trend after earnings beat expectations, with technical support holding and upside targets forming above key resistance levels.
MRNA Starts 2026 Volatile: Examining Rally & Pullback, Outsized Options
Moderna (MRNA) experienced a wild start to 2026, with shares nearly doubling before pulling back 20% from the recent 52-week high. Rick Ducat dives into technical trends to watch and the various suppo...
Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript
Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript
Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms
Moderna Inc. (NASDAQ: MRNA) on Friday reported a fourth-quarter loss of $2.11, beating the expected loss of $2.59, lower than a loss of $2.91 a year ago.
Moderna Narrows Loss, Reiterates 10% Revenue Growth Target
Moderna said it continues to target 10% revenue growth this year, as the company's fourth-quarter loss narrowed from a year earlier.
Moderna Reports a Narrower-Than-Expected Loss. The Stock Falls After Earnings.
Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million.
Moderna beats fourth-quarter revenue estimates
Moderna reported fourth-quarter revenue above Wall Street estimates on Friday, banking on better-than-expected sales of its COVID-19 vaccine in the U.S.